A private equity fund located in the Central US with roughly $1 billion under management intends to make allocations in the tens of millions on a case-by-case basis over the first half of 2013. The firm is generalist and invests across sectors, but has a specific interest in life sciences & medical technologies. Within this space, the firm is opportunistic in almost every aspect, but does require that an issuer be EBITDA-positive. This means that a firm must have at least one product on the market generating revenue to be of interest. Though the firm has looked at and invested in therapeutics and medtech companies historically, a primary interest currently is service providers such as CROs and CMOs.
Popular Topics
Listen to the Podcast
Top Posts
- Hot Investor Profile: USA-Based Family Office Looks for Medical Devices, Diagnostics, Digital Health Companies Close to Exit
- Decoding the Mysteries Behind the Low Success Rate of Life Science Startups
- Surge in Family Offices: Investing in Healthcare
- Hot Investor Profile: Pharma Company with US and China Offices Seeks Early and Late-Clinical Stage Assets in Pediatrics, Respiratory, Oncology, and More
- Interview with Jim MacKrell, Associate Vice President & Head of East Coast (US) Venture Science – Lilly New Ventures, Eli Lilly and Company
- Interview with Dr. Gennady Bratslavsky (Avicella Capital) on RESI Experience from an Investor’s Point of View
- Drug Development: What Does It Cost, and Who Has The Capital?
- Webinar Series Empowering Early-Stage Life Science Entrepreneurs
- Hot Investor Profile: Impact Venture Fund Invests in Solutions Targeting the Aging Population, Focused on Europe-Based Companies
- Michael Langer, Former Pear Therapeutics Executive, and Family Office Entrepreneur Discusses Startup Investing in the Life Science Domain
Recent Posts
- Hot Investor Profile: Pharma Company with US and China Offices Seeks Early and Late-Clinical Stage Assets in Pediatrics, Respiratory, Oncology, and More
- Hot Investor Profile: USA-Based Family Office Looks for Medical Devices, Diagnostics, Digital Health Companies Close to Exit
- Hot Investor Profile: Impact Venture Fund Invests in Solutions Targeting the Aging Population, Focused on Europe-Based Companies
- Hot Investor Profile: Corporate VC Seeks Digital Health and Regenerative Medicine Companies Across the Globe
- Guaranteed Investor Audience for Early-Stage Innovators at RESI Pitch Competition
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Contact us
+1 (617) 600-0668
Info@lifesciencenation.com
Archives
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 
Leave a comment